These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31583739)

  • 1. Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials.
    Pai RK; Kleiner DE; Hart J; Adeyi OA; Clouston AD; Behling CA; Jain D; Kakar S; Brahmania M; Burgart L; Batts KP; Valasek MA; Torbenson MS; Guindi M; Wang HL; Ajmera V; Adams LA; Parker CE; Feagan BG; Loomba R; Jairath V
    Aliment Pharmacol Ther; 2019 Nov; 50(10):1100-1111. PubMed ID: 31583739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score.
    Pai RK; Jairath V; Hogan M; Zou G; Adeyi OA; Anstee QM; Aqel BA; Behling C; Carey EJ; Clouston AD; Corey K; Feagan BG; Kleiner DE; Ma C; McFarlane SC; Noureddin M; Ratziu V; Valasek MA; Younossi ZM; Harrison SA; Loomba R
    Hepatology; 2022 Oct; 76(4):1150-1163. PubMed ID: 35332569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study.
    Rastogi A; Shasthry SM; Agarwal A; Bihari C; Jain P; Jindal A; Sarin S
    APMIS; 2017 Nov; 125(11):962-973. PubMed ID: 29076589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease.
    Forlano R; Mullish BH; Giannakeas N; Maurice JB; Angkathunyakul N; Lloyd J; Tzallas AT; Tsipouras M; Yee M; Thursz MR; Goldin RD; Manousou P
    Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2081-2090.e9. PubMed ID: 31887451
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Automated quantification and architectural pattern detection of hepatic fibrosis in NAFLD.
    Gawrieh S; Sethunath D; Cummings OW; Kleiner DE; Vuppalanchi R; Chalasani N; Tuceryan M
    Ann Diagn Pathol; 2020 Aug; 47():151518. PubMed ID: 32531442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. qFIBS: An Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis.
    Liu F; Goh GB; Tiniakos D; Wee A; Leow WQ; Zhao JM; Rao HY; Wang XX; Wang Q; Wan WK; Lim KH; Romero-Gomez M; Petta S; Bugianesi E; Tan CK; Harrison SA; Anstee QM; Chang PJ; Wei L
    Hepatology; 2020 Jun; 71(6):1953-1966. PubMed ID: 31600834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials.
    Davison BA; Harrison SA; Cotter G; Alkhouri N; Sanyal A; Edwards C; Colca JR; Iwashita J; Koch GG; Dittrich HC
    J Hepatol; 2020 Dec; 73(6):1322-1332. PubMed ID: 32610115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials.
    Brunt EM; Kleiner DE; Wilson LA; Sanyal AJ; Neuschwander-Tetri BA;
    Hepatology; 2019 Aug; 70(2):522-531. PubMed ID: 30549292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deep learning-based quantification of NAFLD/NASH progression in human liver biopsies.
    Heinemann F; Gross P; Zeveleva S; Qian HS; Hill J; Höfer A; Jonigk D; Diehl AM; Abdelmalek M; Lenter MC; Pullen SS; Guarnieri P; Stierstorfer B
    Sci Rep; 2022 Nov; 12(1):19236. PubMed ID: 36357500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histopathology, grading and staging of nonalcoholic fatty liver disease.
    Kleiner DE
    Minerva Gastroenterol Dietol; 2018 Mar; 64(1):28-38. PubMed ID: 28948754
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
    McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
    J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic sonic hedgehog protein expression measured by computer assisted morphometry significantly correlates with features of non-alcoholic steatohepatitis.
    Estep M; Mehta R; Bratthauer G; Alaparthi L; Monge F; Ali S; Abdelatif D; Younoszai Z; Stepanova M; Goodman ZD; Younossi ZM
    BMC Gastroenterol; 2019 Feb; 19(1):27. PubMed ID: 30744560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathology of alcoholic liver disease, can it be differentiated from nonalcoholic steatohepatitis?
    Sakhuja P
    World J Gastroenterol; 2014 Nov; 20(44):16474-9. PubMed ID: 25469015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver biopsy in the real world-reporting, expert concordance and correlation with a pragmatic clinical diagnosis.
    Kim HP; Idowu MO; Mospan AR; Allmon AG; Roden M; Newsome P; Lok AS; Thuluvath PJ; Taunk J; Fried MW; Sanyal AJ; Barritt AS;
    Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1472-1480. PubMed ID: 34694013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comparison of Brunt's Criteria, the Non-Alcoholic Fatty Liver Disease Activity Score (NAS), and a Proposed NAS Scoring that Includes Fibrosis in Non-Alcoholic Fatty Liver Disease Staging.
    Santiago-Rolón A; Purcell D; Rosado K; Toro DH
    P R Health Sci J; 2015 Dec; 34(4):189-94. PubMed ID: 26602577
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantifying and monitoring fibrosis in non-alcoholic fatty liver disease using dual-photon microscopy.
    Wang Y; Wong GL; He FP; Sun J; Chan AW; Yang J; Shu SS; Liang X; Tse YK; Fan XT; Hou J; Chan HL; Wong VW
    Gut; 2020 Jun; 69(6):1116-1126. PubMed ID: 31563875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children.
    Kleiner DE; Makhlouf HR
    Clin Liver Dis; 2016 May; 20(2):293-312. PubMed ID: 27063270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathology of non-alcoholic fatty liver disease.
    Bedossa P
    Liver Int; 2017 Jan; 37 Suppl 1():85-89. PubMed ID: 28052629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Familial non-alcoholic steatohepatitis leading to hepatocellular carcinoma.
    Neuman MG; Cohen LB; Malnick S
    Chem Biol Interact; 2020 May; 323():109054. PubMed ID: 32217109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.